Skip to content
DataLookout
Menu

EXALIVERNCT07467512

Exercise for an Aging Liver (EXALIVER)

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 15 words
    • Start date changed from estimate of Mar 2026 to Mar 1, 2026
    • Secondary endpoints: details revised at 10 of 41 entries
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change in hepatic fat content
Timeframe: Change from baseline to 12 weeks
Change in liver inflammation and fibrosis
Timeframe: Change from baseline to 12 weeks
Change in liver stiffness
Timeframe: Change from baseline to 12 weeks.

Secondary (41)

Change in Enhanced Liver Fibrosis (ELF) Score
Change in Pro-C3 serum levels
Change in NIS4 serum biomarker of liver fibrosis
Change in Metabolomics Advanced Steatohepatitis Fibrosis Score (MASEF)
Change in visceral adipose tissue
Show 36 moreShow less
Change in pancreatic fat content
Change in abdominal subcutaneous adipose tissue
Change in abdominal intermuscular fat content
Change in abdominal intramuscular fat content
Change in abdominal skeletal muscle tissue
Change in values of fasting glucose
Change in values of HbA1c
Change in values of fasting insulin
Change in levels of mean glucose (Continuous Glucose Monitoring)
Change in fasting lipid profile
Change in alkaline phosphatase
Change in alanine aminotransferase (ALT)
Change in gamma-glutamyl transferase (GGT)
Change in total bilirubin
Change in creatinine
Change in estimated glomerular filtration rate (eGFR)
Change in values of C-reactive protein
Change in values of interleukin 6
Change in blood pressure
Change in waist, hip and neck circumference
Change in body weight
Change in moderate-to-vigorous physical activity (MVPA)
Change in light physical activity
Change in sedentary time
Change in total activity counts
Change in Subjective sleep quality
Change in total sleep time
Change in Cardiorespiratory Fitness
Change in Lower-body muscular performance
Change in Upper muscular strength
Change in Quality of life
Change EuroQol Visual Analogue Scale (EQ-VAS) score
Change in mid-thigh subcutaneous adipose tissue area
Change in mid-thigh intramuscular fat content
Change in mid-thigh intermuscular fat content
Change in mid-thigh skeletal muscle cross-sectional area

Arms and interventions

Older adults with at risk MASH who exerciseExperimental

Older adults with Metabolic Dysfunction-Associated SteatoHepatitis aged 70 years or older who will complete the supervised 12-week exercise program.

Middle-age adults with at risk MASH who exerciseExperimental

Middle-aged adults (40 to 60 years old) with at-risk metabolic dysfunction-associated SteatoHepatitis (MASH) who will complete a supervised 12-week exercise program

Middle-age adults with MASLD who exerciseExperimental

Middle-aged adults (40 to 60 years old) with metabolic dysfunction-associated steatotic liver disease (MASLD) who will complete a supervised 12-week exercise program. This study arm will not recruit new participants. Instead, participants will be selected from a concluded clinical trial (NCT05897073; Study Arm: Experimental - Supervised Exercise Intervention), in which they completed the same exercise program and the same study outcome assessments of the present trial. These participants will be matched by sex, age and potential confounders to the individuals enrolled in the "Middle-aged adults with at-risk MASH who exercise" arm of the present study.

Middle-age adults with MASLD receiving usual careActive comparator

Middle-aged adults (40 to 60 years old) with metabolic dysfunction-associated steatotic liver disease (MASLD) who receive usual care. This study arm will not recruit new participants. Instead, participants will be selected from a concluded clinical trial (NCT05897073, Study Arm: No Intervention: Usual-care control group), in which they received usual care and the same study outcome assessments of the present trial. These participants will be matched by sex, age and potential confounders to the individuals enrolled in the "Middle-aged adults with at-risk MASH who exercise" arm of the present study.

Behavioral: Exercise, Usual Care

Sites

1 site in 1 country

  • Hospital General Universitario Gregorio MarañonMadrid, Madrid, Spain